Expectations trend
FY2027 · fiscal year ending 2027-11-30 · fmp
Cryo-Cell International Inc (CCEL)
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$4.95-2.37%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.02 → 0.02 EPS · FY ending Nov 30, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CCEL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating income improves to positive territory | Cryo-Cell is improving its operating income, rising to $765,134 in 2026-Q1 from a loss of nearly $4 million in 2025-Q4. | Intact | operating income falls below $0 in any quarter next year | Operating income: $2.194M FY2026-Q3; GAAP. Published target: >= $765,000 in operating income next 4 quarters. Target period is not explicitly aligned with this observation. Oct 9, 20262,193,731 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-11-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, small-cap improvement story rather than a proven durable compounder, since earnings remain loss-making overall. The long-term thesis is intact, and recent financial performance has strengthened, but the evidence is still mixed and confidence is medium.
The valuation signal is cheap, while the model shows a 1.36 premium versus peers and an expectations gap of -0.51, suggesting the measures do not point in one clear direction. The priced-in assessment is tagged justified, with low fragility; the evidence does not specify exactly what operating outcome the market assumes.
Near-term results could remain uneven: the estimated miss probability is 0.5, reflecting erratic earnings surprises and the company’s smaller size. Over the multi-year view, operating income has improved from a loss in 2025-Q4 to a profit in 2026-Q2 while revenue stayed around $7.7M to $8.0M, consistent with management’s stated priority. Listing compliance remains a concern, though the company submitted a plan accepted by NYSE American.
The main swing factor is whether operating improvement continues while the company regains compliance with listing standards. A weakening jobs trend could increase recession concerns for cyclical businesses, while continued strength from healthcare bellwethers such as HCA, THC, and EHC could support the sector backdrop. Misses or weaker guidance from those companies could instead weaken that support.
For the next 1 to 3 years, CCEL’s long-term thesis rests on sustaining better operating results and resolving listing-compliance concerns; the recent improvement is encouraging, but high risk and uneven earnings leave the case uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Regain compliance with NYSE listing standards |
| The company aims to regain compliance with NYSE listing standards, which would stabilize its market presence. |
| Improving |
| failure to regain compliance by end of 2026 |
Compliance plan accepted May 2026 vs target end-2026 NYSE accepted CCEL's plan to regain compliance with continued listing standards on May 6, 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Management received a notice of non-compliance in 2026-Q1 and submitted a compliance plan accepted by NYSE American in 2026-Q2. The trajectory shows active regulatory engagement but no financial metrics directly tied to compliance progress. Delivery assessment Aug 6, 2026 |
Revenue growth at or above analyst expectations | A supporting condition in Cryo-Cell International Inc's published investment case. The stated target is >= 0.5% YoY revenue growth in FY27. | Intact | revenue growth falls below 0% in FY27 | Revenue growth: -0.02% FY2026-Q3; GAAP. Published target: >= 0.5% YoY revenue growth in FY27. Annual target cannot be compared with a quarterly or TTM observation. Oct 9, 2026-0.016306 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.07 → $0.02 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-07-25 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-07-26 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-07-27 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-07-28 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-07-29 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-07-30 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-07-31 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-01 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-08-02 | $0.07 | $31,500,000 | 1 / 1 |
| 2026-08-03 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-04 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-05 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-06 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-07 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-08 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-09 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-10 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-11 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-12 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-13 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-14 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-15 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-16 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-17 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-18 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-19 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-20 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-21 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-22 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-23 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-24 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-25 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-26 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-27 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-28 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-29 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-30 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-08-31 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-01 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-02 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-03 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-04 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-05 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-06 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-07 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-08 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-09 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-10 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-11 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-12 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-13 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-14 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-15 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-16 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-17 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-18 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-19 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-20 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-21 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-22 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-23 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-24 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-25 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-26 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-27 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-28 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-29 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-09-30 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-01 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-02 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-03 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-04 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-05 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-06 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-07 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-08 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-09 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-10 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-11 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-12 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-13 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-14 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-15 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-16 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-17 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-18 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-19 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-20 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-21 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-22 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-23 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-24 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-25 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-26 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-27 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-28 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-29 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-30 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-10-31 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-11-01 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-11-02 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-11-03 | $0.02 | $28,413,000 | 1 / 1 |
| 2026-11-04 | $0.02 | $28,413,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.